Literature DB >> 22222857

Is adjunctive corticosteroid beneficial in pneumococcal meningitis in a region with high rates of resistance to penicillin and ceftriaxone?

Soo-Youn Moon1, Doo Ryeon Chung, Shin-Woo Kim, Hyun Ha Chang, Hyuck Lee, Dong Sik Jung, Yeon-Sook Kim, Sook In Jung, Seong Yeol Ryu, Sang Taek Heo, Chisook Moon, Hyun Kyun Ki, Jun Seong Son, Ki Tae Kwon, Sang Yop Shin, Jin Seo Lee, Seung Soon Lee, Ji-Young Rhee, Cheol-In Kang, Kyong Ran Peck, Jae-Hoon Song.   

Abstract

The role of adjunctive corticosteroids remains controversial in meningitis by penicillin-resistant pneumococci. We determined the effect of adjunctive corticosteroids in adults with pneumococcal meningitis in a region with a high rate of penicillin resistance. A multicenter, retrospective cohort study was conducted between 1998 and 2008 in Korea. The mortality and neurological sequelae were evaluated. Among 93 patients with pneumococcal meningitis, adequate adjunctive corticosteroids were given in 45.2%. The penicillin resistance rate was 60.0%, and 42.1% were nonsusceptible to ceftriaxone. The 30-day mortality rates in the group receiving adequate corticosteroid therapy, the group in which corticosteroid was not given, and that inadequately given were 24.3, 31.6, and 27.3%, respectively, and there was no difference between the groups. The rates of development of neurological sequelae were 34.3, 33.3, and 43.5%, respectively. Multivariate analysis showed that adequate corticosteroids did not reduce mortality (HR 0.773, 95% CI 0.293-2.040) and neurologic sequelae (HR 0.604, CI 0.262-1.393). Propensity-adjusted analysis showed that adjunctive corticosteroid was not associated with time to death (HR 0.949, CI 0.374-2.408), however, a decreasing tendency was shown in neurologic sequelae in the adequate corticosteroid group (HR 0.479, CI 0.207-1.110). In conclusion, adjunctive corticosteroids did not affect mortality in adults with pneumococcal meningitis in a region with high rates of resistance to penicillin and ceftriaxone; however, the patients receiving adequate corticosteroid therapy tended to develop neurologic sequelae less frequently.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222857     DOI: 10.1007/s00415-011-6373-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  29 in total

1.  Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study.

Authors:  Jean-Damien Ricard; Michel Wolff; Jean-Claude Lacherade; Bruno Mourvillier; Nadia Hidri; Guilène Barnaud; Guillaume Chevrel; Lila Bouadma; Didier Dreyfuss
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

2.  Changing etiology of community-acquired bacterial meningitis in adults: a nationwide multicenter study in Korea.

Authors:  S-Y Moon; D R Chung; S-W Kim; H H Chang; H Lee; D S Jung; Y-S Kim; S I Jung; S Y Ryu; S T Heo; C Moon; H K Ki; J S Son; K T Kwon; S Y Shin; J S Lee; S S Lee; J-Y Rhee; J-A Lee; M K Joung; H S Cheong; K R Peck; J-H Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-01       Impact factor: 3.267

3.  Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988.

Authors:  P B McIntyre; C S Berkey; S M King; U B Schaad; T Kilpi; G Y Kanra; C M Perez
Journal:  JAMA       Date:  1997-09-17       Impact factor: 56.272

4.  Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000.

Authors:  Daryl Hoban; Fernando Baquero; Vaughan Reed; David Felmingham
Journal:  Int J Infect Dis       Date:  2005-09       Impact factor: 3.623

Review 5.  Corticosteroids for acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Peter McIntyre; Jan de Gans; Kameshwar Prasad; Diederik van de Beek
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

6.  EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.

Authors:  A Chaudhuri; P Martinez-Martin; P M Martin; P G E Kennedy; R Andrew Seaton; P Portegies; M Bojar; I Steiner
Journal:  Eur J Neurol       Date:  2008-07       Impact factor: 6.089

7.  Corticosteroids for acute adult bacterial meningitis.

Authors:  D van de Beek
Journal:  Med Mal Infect       Date:  2009-04-21       Impact factor: 2.152

8.  Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  M M París; S M Hickey; M I Uscher; S Shelton; K D Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa.

Authors:  Matthew Scarborough; Stephen B Gordon; Christopher J M Whitty; Neil French; Yasin Njalale; Alex Chitani; Timothy E A Peto; David G Lalloo; Eduard E Zijlstra
Journal:  N Engl J Med       Date:  2007-12-13       Impact factor: 91.245

Review 10.  Steroids in adults with acute bacterial meningitis: a systematic review.

Authors:  Diederik van de Beek; Jan de Gans; Peter McIntyre; Kameshwar Prasad
Journal:  Lancet Infect Dis       Date:  2004-03       Impact factor: 25.071

View more
  2 in total

1.  CRH promotes S. pneumoniae growth in vitro and increases lung carriage in mice.

Authors:  Colette G Ngo Ndjom; Harlan P Jones
Journal:  Front Microbiol       Date:  2015-04-08       Impact factor: 5.640

2.  Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients.

Authors:  Aaron M Cook; G Morgan Jones; Gregory W J Hawryluk; Patrick Mailloux; Diane McLaughlin; Alexander Papangelou; Sophie Samuel; Sheri Tokumaru; Chitra Venkatasubramanian; Christopher Zacko; Lara L Zimmermann; Karen Hirsch; Lori Shutter
Journal:  Neurocrit Care       Date:  2020-06       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.